TMG Investigators Dr. Peter Dzongowski, Dr. Michael Jones, and Dr. Sean Peterson were all recently involved in the GSK trial AReSVi 006, evaluating a vaccine candidate for Respiratory Syncytial Virus (RSV). Recruitment was highly successful for all three investigators, whose work has helped lead to the first RSV vaccine candidate to show statistically significant and [...]
TMG Investigator Dr. Anil Gupta was recently asked to assist in the presentation of strategies for preventing COVID progression and transmission in the outpatient setting, including the latest therapeutic developments. This effort was supported by an educational grant from Merck Sharp & Dohme Corp. The presentation linked below will define the sub-populations that are most [...]
Earlier this year, we reported on the positive findings of a Covid-19 treatment study, conducted by lead study author and TMG Investigator Dr. Anil Gupta. We are now proud to highlight that as of November 18, 2021 this research has been published in the prestigious New England Journal of Medicine. It is among the most [...]
London, UK, 9 September 2021 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced positive high-level results from the MANDALA and DENALI Phase III trials of a new, fixed-dose combination inhaler for those who suffer from asthma. TMG Investigators Dr. Syed Anees, Dr. Peter Dzongowski, Dr. Anil Gupta, Dr. Sam Henein and Dr. [...]
UPDATE 28/10/2021 Dr. Gupta’s work as lead researcher on this study has been published in The New England Journal of Medicine, in an article titled Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. You can find a link to the article on The Journal‘s website, here: https://www.nejm.org/doi/full/10.1056/NEJMoa2107934?query=featured_home UPDATE 30/8/2021 Dr. Gupta has given two significant interviews [...]
A round of applause for our research site physicians Dr Sam Henein and Dr Michael O'Mahony for their participation in the Amarin REDUCE-IT hypertriglyceridemia study! After more than a decade of development and testing, VAZKEPA becomes the first and only European Commission-approved treatment to reduce cardiovascular risk in high-risk, statin-treated adult patients who have elevated [...]
On the last weekend of October TMG held it's first meeting exclusively for our TMG site study coordinators in a cool and rainy Grand Bend, Ontario. The meeting was co-sponsored by TMG and the top-performing TMG investigators from 2017, as a way of recognizing the contribution our study coordinators made to the success of our [...]
TMG recently attended the 2018 Society of Clinical Research Sites Global Site Solutions Summit held October 12-14 in Boca Raton, Florida. The SCRS Global Summit is an opportunity for research sites to share best practices, learn about the future of technology in research, and to work together to build better businesses and develop new [...]
TMG’s revised ICH GCP training program, reflecting the Integrated Addendum to ICH GCP E6(R2), has met the minimum criteria for mutual recognition by TransCelerate BioPharma Inc. Investigators and site personnel who complete a TransCelerate recognised training program such as TMG’s may be able to use their training certificates across TransCelerate Member Companies, of which there [...]
TMG will be attending the 2017 CTO Clinical Trials Conference at the Delta Toronto Hotel on March 8 – 9, 2017. Clinical Trials Ontario (CTO) is an independent not-for-profit organization established with support from the Government of Ontario. Their mandate is to improve Ontario’s clinical trials environment and attract clinical trial investment to the province. [...]
